Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis

Feng, Fan; Jiang, Qiyu; Jia, Hui; Sun, Hongbin; Chai, Yantao; Li, Xiaojuan; Rong, Guanghua; Zhang, Yingshi; Li, Zhengping

doi:10.1016/j.phrs.2018.06.021

Cited by 58 publications

(39 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, a large proportion of patients with HCC often suffer from advanced-stage disease (e.g., advanced HCC, Barcelona Clinic Liver Cancer stage B or C) at initial diagnosis. This subset of patients is unsuitable for surgical resection and is associated with poor clinical outcome or prognosis 7,8 .…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents

et al. 2019

View full text Add to dashboard Cite

Molecular targeted agents, such as sorafenib, remain the only choice of an antitumor drug for the treatment of advanced hepatocellular carcinoma (HCC). The Notch signaling pathway plays central roles in regulating the cellular injury/stress response, anti-apoptosis, or epithelial-mesenchymal transition process in HCC cells, and is a promising target for enhancing the sensitivity of HCC cells to antitumor agents. The ADAM metalloprotease domain-17 (ADAM-17) mediates the cleavage and activation of Notch protein. In the present study, microRNA-3163 (miR-3163), which binds to the 3′-untranslated region of ADAM-17, was screened using online methods. miRDB and pre-miR-3163 sequences were prepared into lentivirus particles to infect HCC cells. miR-3163 targeted ADAM-17 and inhibited the activation of the Notch signaling pathway. Infection of HCC cells with miR-3163 enhanced their sensitivity to molecular targeted agents, such as sorafenib. Therefore, miR-3163 may contribute to the development of more effective strategies for the treatment of advanced HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Moreover, about 50% of the total number of liver cancer cases and deaths worldwide occur in China. 4 However, most patients with HCC are diagnosed at late stages, when the beneficial treatments of hepatic resection, ablation and liver transplantation cannot be applied; thus, only a minority of patients with early-stage HCC are eligible for this procedure. Approximately 90% of primary liver cancers are hepatocellular carcinoma (HCC).…”

Section: Introductionmentioning

confidence: 99%

“…3 In recent years, combination therapy with pirarubicin (THP) in transarterial chemoembolization (TACE) and Sorafenib has been identified as being potentially useful as a first-line treatment for advanced HCC patients. 4 However, most patients with HCC are diagnosed at late stages, when the beneficial treatments of hepatic resection, ablation and liver transplantation cannot be applied; thus, only a minority of patients with early-stage HCC are eligible for this procedure. 5,6 It is well known that hepatocarcinogenesis is a complex multi-step process, that the altering of many signalling cascades could affect important oncogenes and tumour suppressors, and that molecular-targeted therapies, such as Sorafenib, which is a small molecular protein kinase inhibitor, could be effective in treating advanced cancer.…”

mentioning

confidence: 99%

MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K‐AKT‐β‐catenin pathways

Xie

Dai

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Membrane‐associated RING‐CH‐1 (MARCH1) is a membrane‐anchored E3 ubiquitin ligase that is involved in a variety of cellular processes. MARCH1 was aberrantly expressed as a tumour promoter in ovarian cancer, but the signalling about the molecular mechanism has not yet been fully illuminated. Here, we first determined that MARCH1 was obviously highly expressed in human hepatocellular carcinoma samples and cells. In addition, our findings demonstrated that the proliferation, migration and invasion of hepatocellular carcinoma were suppressed, but the apoptosis was increased, as a result of MARCH1 knockdown by either siRNA targeting MARCH1 or pirarubicin treatment. Conversely, the proliferation, migration and invasion of hepatocellular carcinoma were obviously accelerated, and the apoptosis was decreased, by transfecting the MARCH1 plasmid to make MARCH1 overexpressed. Moreover, in vivo, the results exhibited a significant inhibition of the growth of hepatocellular carcinoma in nude mice, which were given an intra‐tumour injection of siRNA targeting MARCH1. Furthermore, our study concluded that MARCH1 functions as a tumour promoter, and its role was up‐regulated the PI3K‐AKT‐β‐catenin pathways both in vitro and in vivo. In summary, our work determined that MARCH1 has an important role in the development and progression of hepatocellular carcinoma and may be used as a novel potential molecular therapeutic target in the future treatment of hepatocellular carcinoma.

show abstract

“…Currently, combination therapies are mainly considered as combinations of different treatment strategies, such as TACE + RFA, TACE + sorafenib, or RFA + sorafenib. [58][59][60][61] On the other hand, there are many reports of combined cytotoxic chemotherapy drugs and molecular targeted drugs or therapeutic antibodies. [62][63][64][65] Although there are very few reports on molecular targeted agents' combination, this type of combination per se is a promising strategy for cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

<p>ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance</p>

Gao¹,

Chen²,

Huang³

et al. 2019

OTT

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the heaviest malignant burdens in China. Molecular targeting agent, sorafenib, is the main therapeutic option for antitumor therapy of advanced HCC, but it is currently too expensive for the public and its therapeutic effect does not satisfy initial expectation. Therefore, it is important to develop more effective molecular targeted therapeutic strategies for advanced HCC. Materials and methods: The antitumor effects of sorafenib or ARQ-197, an antagonist of c-MET (tyrosine-protein kinase Met or hepatocyte growth factor receptor), were examined by MTT or in murine tumor model. The effect of ARQ-197 on epithelial-mesenchymal transition (EMT) or multidrug resistance (MDR) was examined by quantitative real-time PCR for the expression of related genes. The clearance of sorafenib in HCC cells was detected by liquid chromatography-mass spectrometry/mass spectrometry. Results: ARQ-197 treatment enhanced the sensitivity of HCC cells to sorafenib. Mechanistic studies indicated that ARQ-197 inhibited the expression of EMT-and MDR-related genes. Moreover, ARQ-197 treatment decelerated the clearance of sorafenib in cultured HCC cells and subcutaneous HCC tumors in nude mice. Conclusion: In the present work, our data suggested that ARQ-197 decelerated the clearance of sorafenib in HCC cells and enhanced the antitumor effect of sorafenib.

show abstract

Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis

Cited by 58 publications

References 66 publications

MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents

MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents

MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K‐AKT‐β‐catenin pathways

<p>ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance</p>

Contact Info

Product

Resources

About